Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Dual targeting of BRAFV600E and ferroptosis results in synergistic anticancer activity via iron overload and enhanced oxidative stress.

Journal of experimental & clinical cancer research : CR - 7 Jan 2026

Hu Jiangnan, Ghosh Chandrayee, Khaket Tejinder P, Yang Zhongyue, Tabdili Yasmine, Alamaw Eden D, Boufraqech Myriem, Dixon Scott J, Kebebew Electron

Abstract excerpt

BACKGROUND: While combination BRAF and MEK inhibitor treatment in BRAFV600E-mutant cancers results in a response, treatment resistance and toxicity are common. Ferroptosis is an iron-dependent form of non-apoptotic cell death. BRAF inhibition has been associated with increased sensitivity to ferroptosis that is dependent on Glutathione Peroxidase 4 (GPX4). METHODS: In vitro, ex vivo, and in vivo models of...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Drug Synergism
Share to Ferroptosis

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Imidazoles

Share to Oxidative Stress

Share to Oximes

Share to Thyroid Carcinoma, Anaplastic

Share to Xenograft Model Antitumor Assays

Source

Open in PubMed Open full text

Identifiers

PMID: 41501927
DOI: 10.1186/s13046-025-03624-z
PMCID: PMC12871017

Genes

BRAF
GPX4

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 9 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Dual targeting of BRAFV600E and ferroptosis results in synergistic anticancer activity via iron overload and enhanced oxidative stress.PMID 41501927Read ↗

Dual targeting of PDPK1 and BRAF V600E is synthetically lethalSemantic proximity Read ↗

CRISPR-Based Gene Dependency Screens reveal Mechanism of BRAF Inhibitor Resistance in Anaplastic Thyroid CancerSemantic proximity Read ↗

Oncogenic RTKs sensitize cancer cells to ferroptosis via c-Myc mediated upregulation of ACSL4Semantic proximity Read ↗

Radiation-Induced Lipid Peroxidation Triggers Ferroptosis and Synergizes with Ferroptosis InducersSemantic proximity Read ↗

USP7 inhibitor P5091 enhances the antitumor efficacy of vemurafenib in BRAFV600E-mutant thyroid cancer via ferroptosis.Semantic proximity Read ↗

Inhibition of BRAF and ERK1/2 has synergistic effects on thyroid cancer growth in vitro and in vivo.Semantic proximity Read ↗

Temozolomide (TMZ) Inhibits Glioma Cell Proliferation by Inducing Ferroptosis: Effect and MechanismSemantic proximity Read ↗

Investigation into the Effect and Mechanism of Temozolomide (TMZ) Inducing Ferroptosis to Inhibit Glioma Cell ProliferationSemantic proximity Read ↗

Dual Inhibition of BRAF-MAPK and STAT3 Signaling Pathways in Resveratrol-Suppressed Anaplastic Thyroid Cancer Cells with BRAF Mutations.Semantic proximity Read ↗

Augmenting MEK inhibitor Efficacy in BRAF Wild-Type Melanoma: Synergistic Effects of Disulfiram Combination TherapySemantic proximity Read ↗

BRAF-activated ARSI suppressed EREG-mediated ferroptosis to promote BRAFV600E (mutant) papillary thyroid carcinoma progression and sorafenib resistance.Semantic proximity Read ↗

Combinative treatment of β-elemene and cetuximab is sensitive to KRAS mutant colorectal cancer cells by inducing ferroptosis and inhibiting epithelial-mesenchymal transformation.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.